Distinguishing Pathway to Precision for c-Met and MET Alterations in NSCLC

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Sandip Patel, MD; and Ignacio I. Wistuba, MD, discuss new therapies for patients with c-Met–overexpressing non–small cell lung cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate safety and efficacy results from clinical trials investigating c-Met–targeted approaches for the management of patients with advanced NSCLC
• Develop approaches to manage common and severe adverse events associated with c-Met-directed therapies.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AbbVie, Inc.

Faculty:

Erminia Massarelli, MD, PhD, MS

Professor and Division Chief, Oncology and Hematology
The University of Texas at Tyler School of Medicine
UT Health East Texas HOPE Cancer Center
Tyler, TX

Erminia Massarelli, MD, PhD, MS, has no relevant financial relationships with ineligible companies.

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine
Section Head, Lung and Head/Neck Tumors
USC Norris Comprehensive Cancer Center
Keck School of Medicine
University of Southern California
Los Angeles, CA

Disclosures: Consultant: Aadi, AffyImmune, ANP Therapeutics, AstraZeneca, BioAtla, Genentech, KaliVir; Grant/Research Support: Genentech, Merck; Stock/Shareholder: Affyimmune, Amgen, Cansera, Epic Sciences, Indee Bio, Johnson & Johnson, Novartis

Sandip Patel, MD

Professor, Medical Oncology
UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
UC San Diego Health
San Diego, CA

Disclosures: Consultant: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Genentech, Illumina, Jazz, Merck, Pfizer; Grant/Research Support: A2bio, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech

Ignacio I. Wistuba, MD

Chair, Department of Translational Pathology
Moffit Cancer Center
Tampa, FL

Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst Therapeutics, Daiichi Sankyo, Flame, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Johnson & Johnson, Merck, Merus, Novartis, Pfizer, Regeneron, Sanofi; Grant/Research Support: 4D, Adaptimmune, Adaptive, Akoya, Amgen, Bayer, Bristol Myers Squibb, EMD Serono, Genentech, Iovance, Johnson & Johnson, Karus, Medimmune, Merck, Novartis, Pfizer, Takeda; Speaker’s Bureau: AstraZeneca, Dava Oncology, Genentech/Roche, Medscape, Merck, Merus, Pfizer, Platform Health, Suzhou Liangyihui Network Technology, Touchpoint Group Holdings

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

Release Date

August 22, 2025

Expiration Date

August 22, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.